Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Iwai M., Tulafu M., Togo S., Kawaji H., Kadoya K., Namba Y., Jin J., Watanabe J., Okabe T., Hidayat M., Sumiyoshi I., Itoh M., Koyama Y., Ito Y., Orimo A., Takamochi K., Oh S., Suzuki K., Hayashizaki Y., Yoshida K., Takahashi K.
56357096800;55818028100;9533914900;57196621148;57193562606;55413965500;57221345975;57202019639;57208252941;56435992700;57202003876;57218355452;57202921569;57225926629;56922531400;57070836300;56922435100;57221017119;57216108710;55725231300;57226207751;
Cancer-associated fibroblast migration in non-small cell lung cancers is modulated by increased integrin α11 expression
2021
Molecular Oncology
15
5
1507
1527
2
Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan; Leading Center for the Development and Research of Cancer Medicine, Juntendo University, Tokyo, Japan; Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan; Preventive Medicine and Applied Genomics Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; RIKEN Preventive Medicine and Diagnosis Innovation Program, Saitama, Japan; Department of Respiratory and Critical Care Medicine, National Center of Gerontology, Beijing Hospital, China; Department of Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine, Jakarta, Indonesia; Departments of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Department of Oral Pathobiological Science and Surgery, Tokyo Dental College, Japan; Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan; Faculty of Biology-Oriented Science and Technology, Kindai University, Wakayama, Japan
Iwai, M., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan; Tulafu, M., Leading Center for the Development and Research of Cancer Medicine, Juntendo University, Tokyo, Japan; Togo, S., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan; Kawaji, H., Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan, Preventive Medicine and Applied Genomics Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, RIKEN Preventive Medicine and Diagnosis Innovation Program, Saitama, Japan; Kadoya, K., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan; Namba, Y., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan; Jin, J., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan, Department of Respiratory and Critical Care Medicine, National Center of Gerontology, Beijing Hospital, China; Watanabe, J., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan; Okabe, T., Leading Center for the Development and Research of Cancer Medicine, Juntendo University, Tokyo, Japan; Hidayat, M., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan, Department of Pulmonology and Respiratory Medicine, Universitas Indonesia Faculty of Medicine, Jakarta, Indonesia; Sumiyoshi, I., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan; Itoh, M., RIKEN Preventive Medicine and Diagnosis Innovation Program, Saitama, Japan; Koyama, Y., Departments of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan, Department of Oral Pathobiological Science and Surgery, Tokyo Dental College, Japan; Ito, Y., Departments of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Orimo, A., Departments of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Takamochi, K., Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan; Oh, S., Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan; Suzuki, K., Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan; Hayashizaki, Y., RIKEN Preventive Medicine and Diagnosis Innovation Program, Saitama, Japan; Yoshida, K., Faculty of Biology-Oriented Science and Technology, Kindai University, Wakayama, Japan; Takahashi, K., Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine, Tokyo, Japan
Cancer-associated fibroblasts (CAFs) regulate cancer progression through the modulation of extracellular matrix (ECM) and cancer cell adhesion. While undergoing a series of phenotypic changes, CAFs control cancer–stroma interactions through integrin receptor signaling. Here, we isolated CAFs from patients with non-small-cell lung cancer (NSCLC) and examined their gene expression profiles. We identified collagen type XI α1 (COL11A1), integrin α11 (ITGA11), and the ITGA11 major ligand collagen type I α1 (COL1A1) among the 390 genes that were significantly enriched in NSCLC-associated CAFs. Increased ITGA11 expression in cancer stroma was correlated with a poor clinical outcome in patients with NSCLC. Increased expression of fibronectin and collagen type I induced ITGA11 expression in CAFs. The cellular migration of CAFs toward collagen type I and fibronectin was promoted via ERK1/2 signaling, independently of the fibronectin receptor integrin α5β1. Additionally, ERK1/2 signaling induced ITGA11 and COL11A1 expression in cancer stroma. We, therefore, propose that targeting ITGA11 and COL11A1 expressing CAFs to block cancer–stroma interactions may serve as a novel, promising anti-tumor strategy. © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
cancer; cancer-associated fibroblast; collagen type I; collagen type XI α1; integrin alpha-11; non-small-cell lung cancer; stroma interaction; transforming growth factor beta
alpha11 integrin; collagen type 1; collagen type 1 alpha1; collagen type 11; collagen type 11 alpha1; fibronectin; fibronectin receptor; integrin; mitogen activated protein kinase 3; retrovirus vector; small interfering RNA; transforming growth factor beta1; unclassified drug; very late activation antigen 5; adult; aged; Article; cancer associated fibroblast; cancer recurrence; cell interaction; cell migration; chemotaxis; clinical article; clinical outcome; controlled study; DNA modification; enzyme linked immunosorbent assay; female; gene expression profiling; human; human cell; human tissue; immunohistochemistry; in vitro study; lung adenocarcinoma; lung fibroblast; lung parenchyma; male; non small cell lung cancer; priority journal; protein expression; protein expression level; protein
John Wiley and Sons Ltd
15747891
33682233
Article
Q1
2332
1019